IA
STRO icon

IFP Advisors’s Sutro Biopharma STRO Stock Holding History

IFP Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed -$18 – 5026
2025
Q3 		$18 Sell
2
-6
-75% -$51 ﹤0.01% 4761
2025
Q2 		$56 Buy
+8
New +$65 ﹤0.01% 4790
2025
Q1 		– Sell
-3
Closed -$55 – 4620
2024
Q4 		$55 Buy
+3
New +$92 ﹤0.01% 4231

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

IFP Advisors's STRO Position: Q4 2025 in Review

IFP Advisors sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 2 shares — an estimated $18 sold.

IFP Advisors first reported a position in STRO in Q4 2024 and held it in 3 quarters. The position peaked at $56 in Q2 2025. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • IFP Advisors reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 2 Sutro Biopharma shares in Q4 2025, an estimated $18.
  • IFP Advisors first reported a position in Sutro Biopharma in Q4 2024 and held it in 3 quarters.
  • IFP Advisors's Sutro Biopharma position peaked at $56 in Q2 2025.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.